Ultrasound to check chemoembolization for liver tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial uses a special ultrasound with a contrast agent to see how well a liver cancer treatment called TACE is working. It may help doctors better understand if the treatment is shrinking the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for a liver tumor treatment called TACE (chemoembolization).
- You are 18 years or older.
- You are medically stable and not seriously ill.
- If you can become pregnant, you must have a negative pregnancy test before the study.
- You do not have an allergy to the contrast agent Lumason (sulfur hexafluoride).
- You agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new ultrasound technique to predict whether chemotherapy will work on colorectal cancer that has spread to your liver. The technique uses sound waves and a special contrast dye to measure blood flow in tumors before treatment starts, which may help doctors know early if the treatment is working.
This study looks at special blood markers in people with liver cancer (hepatocellular carcinoma) who are about to have a procedure called TACE. The goal is to see if these markers can help predict how well the treatment works. You may be able to join if you are getting TACE as part of your standard care.
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
This study tests whether a special ultrasound scan with contrast can help doctors find kidney cancer that comes back after a procedure called ablation. It may help improve monitoring by comparing the ultrasound results with CT or MRI scans done soon after treatment.
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
Hear when a new Liver Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.